QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: mol.107.036566v1 72/5/1289    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by He, F. Articles by Song, Z.-H. Search for Related Content PubMed PubMed Citation Articles by He, F. Articles by Song, Z.-H.

Involvement of the 90-kDa Heat Shock Protein (Hsp-90) in CB2 Cannabinoid Receptor-Mediated Cell Migration: A New Role of Hsp-90 in Migration Signaling of a G Protein-Coupled Receptor

Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky (F.H., Z.-H.Q., J.C., W.P., Z.-H.S.); and Institute of Cell Biology, College of Life Science, Beijing Normal University, Beijing, People's Republic of China (F.H., D.-C.H.)

Received March 28, 2007; accepted August 14, 2007

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
The endocannabinoid 2-arachidonoylglycerol (2-AG) enhances cell migration through the CB2 cannabinoid receptor. In this study, using an immunoprecipitation and mass spectrometry-based proteomic approach, we first identified the 90-kDa heat shock protein (Hsp90), a chaperone protein with novel signaling functions, as a CB2-interacting protein. The CB2/Hsp90 interaction was confirmed in human embryonic kidney 293 cells expressing transfected CB2 and in differentiated HL-60 cells expressing endogenous CB2, by coimmunoprecipitation and Western blot experiments, as well as by treatment with geldanamycin (GA), a specific Hsp90 inhibitor. Disruption of the CB2/Hsp90 interaction by treatment with GA or reducing Hsp90 levels with specific short interfering RNAs markedly inhibited 2-AG-induced cell migration, demonstrating that Hsp90 is crucial for 2-AG-induced cell migration. 2-AG treatment resulted in a CB2-mediated stimulation of Rac1 activity, and treatment with GA blocked 2AG-induced activation of Rac1. It is noteworthy that expression of the dominant-negative form of Rac1 reduced 2-AG-induced cell migration. These data demonstrate that 2-AG-induced activation of Rac1 is essential for 2-AG-induced cell migration, and the CB2/Hsp90 interaction is needed for 2-AG-induced activation of Rac1. Furthermore, 2-AG-induced Rac1 activation was sensitive to pertussis toxin treatment, hence involving G_i proteins. In addition, treatment with GA significantly inhibited the CB2/G_i2 interaction. As a whole, our data indicate that Hsp90 may serve as scaffold to keep the CB2 receptor and its signaling components, including G_i2, in proximity, thus facilitating CB2-mediated signaling to cell migration through the G_i-Rac1 pathway. By demonstrating that Hsp90 is essential for CB2-mediated signaling to cell migration, this study reveals a novel role of Hsp90 in the signaling events mediated by a G protein-coupled receptor.

2-Arachidonoylglycerol (2-AG) is an endogenous ligand for the cannabinoid receptor (Mechoulam et al., 1995; Sugiura et al., 1995). 2-AG binds to both CB1 and CB2, and it exhibits a variety of cannabimimetic activities in vitro and in vivo (Mechoulam et al., 1995; Sugiura et al., 1995; Sugiura and Waku, 2000; Kogan and Mechoulam, 2006). Evidence is accumulating that 2-AG is a physiologically essential molecule that acts both as a novel type of neuromodulator and as an important immunomodulator (Sugiura et al., 2004; Kogan and Mechoulam, 2006).

Cell migration is of paramount importance in physiological activities of, for example, leukocyte-mediated immune surveillance, as well as in pathological processes such as leukemia metastasis. Endocannabinoid 2-AG has been reported to enhance the migration of a variety of cell types (e.g., normal leukocytes as well as differentiated and undifferentiated leukemia cells) through the CB2 receptor (Jordà et al., 2002, 2003; Kishimoto et al., 2003; Oka et al., 2004). Despite the important roles that CB2 receptors play in the migration of normal leukocytes and leukemia cells, the identification of molecular mechanisms underlying CB2 receptor-mediated cell migration is still in its early stages.

Recent evidence has strongly suggested that GPCRs interact with a variety of proteins in addition to G proteins, which can participate in the trafficking, signaling, fine-tuning, and allosteric regulation of GPCRs (Brady and Limbird, 2002; Bockaert et al., 2004; Tilakaratne and Sexton, 2005). In this study, to better define the CB2 receptor complex involved in cell migration, we first used a coimmunoprecipitation and mass spectrometry-based proteomic approach to study the CB2 receptor-interacting proteins. We then focused on Hsp90, one of the CB2 receptor-interacting proteins that we identified using the proteomic technology.

Hsp90 is a highly conserved protein. Its role as a molecular chaperone in preventing protein aggregation and in promoting refolding of denatured proteins has been well studied (Rutherford and Zuker, 1994; Bohen et al., 1995; Pratt, 1997; Gaestel, 2006). More recently, interest in Hsp90 has expanded to include an apparently mechanistically distinct function. By forming heterocomplexes with its substrates, Hsp90 has been shown to play a key role as scaffolding site for various signaling events under nonstress conditions (Rutherford and Zuker, 1994; Bohen et al., 1995; Pratt, 1997; Gaestel, 2006).

In this study, we reveal that there are interactions between Hsp90 and CB2 receptors in HEK293 cells expressing transfected CB2 receptors as well in differentiated HL-60 cells expressing endogenous CB2 receptors. Furthermore, we demonstrate that Hsp90 is involved in the CB2 receptor signaling and CB2 receptor-mediated cell migration.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Materials. The following primary antibodies were used in our experiments: mouse monoclonal anti-FLAG M2 antibody (Sigma-Aldrich, St. Louis, MO), rabbit polyclonal anti-CB2 antibody (Cayman Chemical, Ann Arbor, MI), mouse monoclonal anti-Hsp90 antibody (BD Biosciences, San Jose, CA), rabbit anti-mouse IgG (Chemicon International, Temecula, CA), His-Tag monoclonal antibody (EMD Biosciences, Madison, WI), mouse monoclonal anti-hemagglutinin antibody (Roche Diagnostics, Indianapolis, IN), rabbit polyclonal anti--actin antibody (Cell Signaling Technology Inc., Danvers, MA), and rabbit polyclonal anti-Rac antibodies (Cytoskeleton, Denver, CO). The horseradish peroxidase-conjugated goat anti-mouse and anti-rabbit secondary antibodies were purchased from GE Healthcare (Chalfont St. Giles, Buckinghamshire, UK). 2-AG was obtained from Tocris Cookson Inc. (Ellisville, MO). SR144528 was from National Institute of Drug Abuse (Bethesda, MD). Geldanamycin was from BIOMOL Research Laboratories (Plymouth Meeting, PA). pIRESneo vector was from BD Biosciences. The plasmid encoding human dominant-negative Rac-1 proteins was obtained from University of Missouri-Rolla cDNA Resource Center (Rolla, MO). Hsp90 siRNA and scrambled siRNA were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). DMEM, RPMI 1640 medium, and EDTA-trypsin were from Thermo Fisher Scientific (Waltham, MA). Lipofectamine 2000 was from Invitrogen (Carlsbad, CA). HEK293 and HL-60 cells were from American Type Culture Collection (Manassas, VA).

Cell Culture. Transfected HEK293 cells were grown in DMEM supplemented with 10% (v/v) fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin, 20 mM L-glutamine, and 500 µg/ml G-418 (Geneticin; Invitrogen). HL-60 promyelocytic leukemia cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin, and 20 mM L-glutamine. Cultures were maintained at 37°C in an atmosphere of 95% air and 5% CO₂. To differentiate HL-60 cells into neutrophil-like cells, 250 µl of DMSO was added to 2 x 10⁶ cells in 20 ml of RPMI 1640 medium, followed by an incubation of 5 days at 37°C in the CO₂ incubator without changing the medium.

DNA Constructs and Transfection. To facilitate coimmunoprecipitation, a FLAG sequence was inserted into the N-terminal of human CB2 receptor contained in mammalian expression vector pIRESneo. Sixteen micrograms of plasmid was transfected into HEK293 cells at a confluence of 80% in 10-cm culture plate using Lipofectamine 2000. Transfected cells were selected in culture medium containing 500 µg/ml G-418, and cell lines stably expressing FLAG-CB2 receptor were established according to a method developed previously (Song and Bonner, 1996; Song et al., 1999). In siRNA knockdown experiments, 2 µg of Hsp90 siRNA or scrambled siRNA was transiently transfected into HEK293 cells stably expressing FLAG-CB2 receptor at a confluence of 80% or differentiated HL-60 cells at a density of 2 x 10⁶ cells/ml, using Lipofectamine 2000. Transient transfection of cells with the dominant-negative Rac1 plasmid (16 µg) was performed using Lipofectamine 2000, according to the manufacturer's instructions. Subsequent assays were performed at 24 h after transfection.

Membrane Preparation and Solubilization. For membrane preparations, cells were washed twice with ice-cold phosphate-buffered saline, scraped off the tissue culture plates, and collected by centrifugation at 1000g for 5 min at 4°C. Subsequently, the cells were homogenized in membrane buffer (50 mM Tris-HCl, 5 mM MgCl₂, and 2.5 mM EDTA, pH 7.4) with a Polytron homogenizer (Kinematica, Basel, Switzerland). After the homogenate was centrifuged at 32,000g for 20 min at 4°C, the pellet was resuspended in membrane buffer containing 1% dodecylmaltoside, and the sample was incubated with rotation for 2 h at 4°C. The solubilized samples were then centrifuged for 20 min at 100,000g for 20 min at 4°C, and the protein content in the supernatant was determined using a Bradford protein assay kit (Bio-Rad, Hercules, CA).

Immunoprecipitation. For coimmunoprecipitation experiments, 500 µg of proteins from solubilized membrane preparations was incubated with 20 µg of primary antibody and 80 µl of protein G-Sepharose beads. After overnight incubation at 4°C, the resins were washed with 10 volumes of solubilization buffer with increasing concentrations of NaCl, and proteins were eluted from beads in sample loading buffer.

In-Gel Digestion and MALDI-TOF-MS. Samples containing immunoprecipitated receptor complex were separated by SDS-PAGE. The Coomassie-stained gel pieces were destained by three cycles of dehydration with 50% acetonitrile (ACN) in 25 mM NH₄HCO₃, pH 8.4, and hydration with 25 mM NH₄HCO₃. The destained protein bands were dried in a vacuum centrifuge. The protein bands were reduced with 10 mM dithiothreitol in 25 mM NH₄HCO₃ for 45 min at 56°C. For alkylation of proteins, the dithiothreitol solution was replaced by 55 mM iodoacetic acid in 25 mM NH₄HCO₃ and incubated for 30 min in the dark. The gel pieces were then washed alternatively with 25 mM NH₄HCO₃ and 25 mM NH₄HCO₃/50% ACN three times, and they were completely dried in a vacuum centrifuge. The gel pieces were incubated with trypsin in 25 mM NH₄HCO₃ at 37°C for 16 h. The digestion peptide fragments were mixed with equal amount of matrix solution (-cyano-cinnamic acid in 50% ACN/0.1% trifluoroacetic acid), and loaded onto target plate. Mass spectra were obtained using a TofSpec 2E MALDI-TOF mass spectrometer (Micromass, Manchester, UK). Proteins were identified based on matching the MS data with the calculated mass values of peptide fragments using Mascot (Matrix Science, London, UK).

Western Blot Analysis. Samples were incubated with 2x Laemmli buffer under reducing conditions at room temperature for 20 min, and proteins were resolved on a 10% SDS-polyacrylamide gel using a minigel electrophoresis system (Invitrogen). Proteins were transferred onto a nitrocellulose membrane for immunodetection with indicated antibodies. The nitrocellulose membranes were blocked with 5% nonfat dry milk in Tris-buffered saline/Tween 20 (TBS-T; 20 mM Tris, 137 mM NaCl, and 0.1% Tween 20, pH 7.6) for 1 h and then incubated overnight at 4°C with the primary antibody. Thereafter, the membranes were washed twice for 10 min each time with TBS-T buffer and incubated with horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. The membranes were then washed three times with TBS-T buffer for 10 min each time, and the antibody-recognized protein bands were visualized using an enhanced chemiluminescence kit from GE Healthcare.

Migration Assay. The migration of differentiated HL-60 cells was assayed using the Transwell inserts (5-µm pore size) and 24-well culture plates (Costar; Corning Life Science, Acton, MA). In brief, 2-AG or vehicle (0.01% DMSO in RPMI 1640 medium) was added to 0.6 ml of the RPMI 1640 medium containing 0.1% bovine serum albumin in the well of the culture plate (the bottom compartment). Subsequently, 1.0 x 10⁶ cells were washed several times, suspended in 0.1 ml of RPMI 1640 medium containing 0.1% bovine serum albumin, and transferred to the Transwell insert (the top compartment). After incubation at 37°C for 4 h in a cell culture incubator, the number of cells that migrated from the top to the bottom compartment was counted using a hemocytometer. For adherent transfected HEK293 cells, Transwell inserts (8-µm pore size) were first coated overnight at 4°C with 5 µg/ml fibronectin. Cells were harvested from the culture dish into a 50-ml centrifuge tube using phosphate-buffered saline-EDTA. Subsequently, the cells were washed with DMEM supplemented with 0.2% bovine serum albumin and centrifuged at 500g. The cell pellets were resuspended in the same medium with a final cell concentration of 1.0 x 10⁶ cell/ml. 2-AG or vehicle (0.01% DMSO in DMEM) was added to 0.6 ml of DMEM supplemented with 0.2% bovine serum albumin in the well of the culture plate (the bottom compartment). The 0.1 ml of transfected HEK293 cells (containing 1.0 x 10⁵ cells) were transferred to the Transwell inserts (the top compartment). After incubation at 37°C for 4 h in cell culture incubator, the Transwell insert was stained with a HEMA 3 staining kit (Fisher Scientific Inc., Houston, TX). Five randomly chosen microscopy fields were photographed. Migrated cells in each filed were quantified by counting using a scorer and the Northern Eclipse software (Empix Imaging Inc. Mississauga, ON, Canada). Results are presented as migration index, which is the ratio of cells migrated in the presence of drug versus cells migrated in the presence of vehicle. Three independent experiments were performed. In each experiment, triplicate was performed for each condition.

Rac1-GTPase Pull-Down Assay. Rac1 activation assay kit was purchased from Cytoskeleton, and assays were performed according to attached protocols. In brief, transfected HEK293 cells with a confluent of 90% in 10-cm culture plate or 1.0 x 10⁷ differentiated HL-60 cells were serum-starved for 18 h. Then, the cells (pretreated with geldanamycin or vehicle: 0.01% DMSO in DMEM or RPMI 1640 medium) were stimulated with 500 nM 2-AG or vehicle (0.01% DMSO in DMEM or RPMI 1640 medium) and immediately lysed with lysis buffer supplied in the kit and centrifuged at 14,000g for 3 min. A portion of each supernatant was diluted in SDS-PAGE sample buffer for detection of total (both GTP- and GDP-bound) Rac1 GTPases. The remaining supernatant fractions were incubated with 20 µl of PAK-PBD-agarose for 1 h at 4°C, followed by washing twice with lysis buffer and wash buffer. Proteins bound to the beads were eluted in 30 µlof2xSDS-PAGE sample buffer, and they were subjected to Western blot analysis.

Data Analysis. The data presented in figures represent mean ± S.E. The figures were generated with the use of GraphPad Prism software (GraphPad Software Inc., San Diego, CA). One-way ANOVA with Newman-Keuls post test was used to compare the data of different treatment groups. The level of significance was chosen as P < 0.01.

	Results

Top Abstract Materials and Methods Results Discussion References

 
Identification of Hsp90 as a CB2 Receptor-Interacting Protein by Proteomic Analysis. A proteomic strategy combining immunoprecipitation and mass spectrometry was used in this study to identify CB2 receptor-interacting proteins. To facilitate the immunoprecipitation of CB2 receptor protein complex, we introduced a FLAG tag sequence at the N-terminal of the human CB2 receptor. In a previous study, we have shown that the FLAG tag sequence does not affect the functions of human CB2 cannabinoid receptor (Zhang et al., 2007).

Using an anti-FLAG antibody, CB2 receptor complex was immunoprecipitated from HEK293 cells stably expressing FLAG-CB2. HEK293 cells transfected with an empty vector were used as a negative control, and they were subjected to the same immunoprecipitation procedure. As shown in lane 4 of Fig. 1, when the immunoprecipitated receptor complex was separated by SDS-PAGE and stained with Coomassie Blue, bands ranging in sizes from 37 to 100 kDa were apparent. In contrast, most of these bands were not present in the negative control sample (Fig. 1, lane 3). These experiments were repeated three times, and similar protein bands profiles were obtained. Bands that appeared only in immunoprecipitates of HEK293 cells stably expressing FLAG-CB2 were excised, subjected to trypsin digestion, and identified by MALDI-TOF-MS. Among the protein bands identified unambiguously by MALDI-TOF-MS were CB2 receptor at approximately 40 kDa and Hsp90 at approximately 90 kDa. As shown in Table 1, eight peptides obtained from tryptic digestion of the 90-kDa band matched with calculated molecular mass for the tryptic peptides of Hsp90.

View larger version (20K): [in this window] [in a new window]   Fig. 1. Identification of Hsp90 as a CB2 receptor-interacting protein by proteomic analysis. Protein staining demonstrating immunoprecipitation of the CB2 receptor protein complex from HEK293 cells stably expressing FLAG-CB2. Lanes 1 and 2 represent membrane preparations from HEK293 cells stably transfected with an empty expression vector and HEK293 cells stably expressing FLAG-CB2, respectively. Lanes 3 and 4 represent immunoprecipitates from HEK293 cells stably transfected with an empty expression vector and HEK293 cells stably expressing FLAG-CB2, respectively. The position of CB2 receptor and Hsp90 identified by mass spectrometry is indicated. The experiment was repeated three times, with similar results.

Verification of the Interaction between Hsp90 and CB2 Receptor. The association of Hsp90 with CB2 receptor was confirmed by coimmunoprecipitation and immunoblotting experiments. First, CB2 receptor complex was pulled down from HEK293 cells stably expressing FLAG-CB2 with an anti-CB2 antibody and immunoblotted with the anti-Hsp90 antibody. As shown in Fig. 2A, top, the Hsp90 band was detected in membranes prepared from HEK293 cells stably expressing FLAG-CB2, as well as HEK293 cells transfected with an empty vector. However, after immunoprecipitation, the Hsp90 band was detected only in immunoprecipitates of HEK293 cells expressing FLAG-CB2 receptor and not in HEK293 cells transfected with the empty vector. This result obtained using anti-CB2 antibody ruled out the possibility that the interaction of Hsp90 with CB2 might be caused by the presence of FLAG epitope, and it indicated that the interaction between Hsp90 and CB2 receptor was indeed specific. Second, to further verify the interaction of Hsp90 with CB2 receptor, coimmunoprecipitation and immunoblotting experiments were carried out in a reverse order; i.e., anti-Hsp90 antibody was used for immunoprecipitation to see whether CB2 receptor could be coimmunoprecipitated. As shown in Fig. 2A, bottom, CB2 band was detected in membrane preparations and immunoprecipitates of HEK293 cells stably expressing FLAG-CB2, but not in membranes and immunoprecipitates prepared from HEK293 cells transfected with the empty vector. These reverse coimmunoprecipitation and immunoblotting experiments provided further evidence for the physical association of Hsp90 with CB2 receptor.

View larger version (13K): [in this window] [in a new window]   Fig. 2. Verification of the interaction between Hsp90 and CB2 receptor. A, confirmation of Hsp90 interaction with CB2 receptor in HEK293 cells stably expressing FLAG-CB2 by coimmunoprecipitation. Top, membranes prepared from HEK293 cells stably expressing FLAG-CB2 and HEK293 cells stably transfected with an empty expression vector were subjected to immunoprecipitation with the anti-CB2 antibody, and they were then immunoblotted with the anti-Hsp90 antibody. Bottom, membranes were subjected to immunoprecipitation with the anti-Hsp90 antibody, and they were then immunoblotted with the anti-CB2 antibody. B, confirmation of Hsp90 interaction with CB2 receptor in differentiated HL-60 cells expressing endogenous CB2 by coimmunoprecipitation. Top, membranes prepared from differentiated HL-60 cells were subjected to immunoprecipitation with the anti-CB2 antibody, and they were immunoblotted with the anti-Hsp90 antibody. Bottom, membranes were subjected to immunoprecipitation with the anti-Hsp90 antibody, and they were then immunoblotted with the anti-CB2 antibody. Control experiments were performed using nonrelevant IgGs (lane 3). The experiment was repeated three times, with similar results.

Effect of Geldanamycin on the Interaction between Hsp90 and CB2 Receptor. Geldanamycin, a small molecule that specifically binds to the ATP-binding pocket in Hsp90, but not other chaperone proteins, alters the tertiary structure of Hsp90, and it prevents Hsp90 from interacting with target proteins (Stebbins et al., 1997). In this study, the effect on geldanamycin on the interaction between Hsp90 and CB2 receptor was investigated. In HEK293 cells stably expressing FLAG-CB2, geldanamycin treatment did not significantly affect the amount of CB2 receptor and Hsp90 in membrane fractions (Fig. 3A, 3 and 4). However, treatment with geldanamycin markedly reduced the amount of Hsp90 pulled down by anti-CB2 antibody in coimmunoprecipitation and immunoblotting studies. In addition, similar results were obtained with differentiated HL-60 cells; i.e., geldanamycin treatment significantly reduced the amount of Hsp90 pulled down by anti-CB2 antibody (Fig. 3B). These data further demonstrate that the interaction of Hsp90 with CB2 receptor is specific.

View larger version (16K): [in this window] [in a new window]   Fig. 3. The effect of geldanamycin on the interaction between Hsp90 and CB2 receptor. A, effect of geldanamycin on the interaction between Hsp90 and CB2 receptor in HEK293 cells stably expressing FLAG-CB2. Cells were treated with 10 µM geldanamycin (GA) for 2 h. Membranes were prepared and subjected to coimmunoprecipitation with anti-CB2 antibody. Then, the samples were immunoblotted with anti-Hsp90 (1) and anti-CB2 antibodies (2). B, effect of geldanamycin on the interaction between Hsp90 and CB2 receptor in differentiated HL-60 cells expressing endogenous CB2. Cells were treated with 10 µM GA for 2 h. Membranes were prepared and subjected to coimmunoprecipitation with the anti-CB2 antibody. Then, the samples were immunoblotted with anti-Hsp90 (1) and anti-CB2 antibodies (2). The experiment was repeated three times, with similar results.

View larger version (6K): [in this window] [in a new window]   Fig. 4. 2-AG-induced, CB2 receptor-mediated cell migration. A, 2-AG-induced migration of HEK293 cells stably expressing FLAG-CB2. 2-AG (500 nM) or vehicle was added to the bottom compartments, and cells were added to the top compartments of the Transwell cell migration system. The system was then incubated for 4 h at 37°C, and the cells migrated to the underside of the porous membrane were determined as described under Materials and Methods. For antagonist treatment, 1 µM SR144528 (SR2) was used. Results are presented as migration index, which is the ratio of cells migrated in the presence of 2-AG versus cells migrated in the presence of vehicle. Data are mean ± S.E. of three independent experiments, each performed in triplicate. **, significant differences (p < 0.01) between experimental groups (ANOVA followed by Newman-Keuls post test). B, 2-AG-induced migration of differentiated HL-60 cells expressing endogenous CB2. 2-AG (500 nM) or vehicle was added to the bottom compartments, and cells were added to the top compartments of the Transwell cell migration system. The system was then incubated for 4 h at 37°C, and the cells migrated to the bottom compartments were determined as described under Materials and Methods. For antagonist treatment, 1 µM SR2 was used. Results are presented as migration index, which is the ratio of cells migrated in the presence of drug versus cells migrated in the presence of vehicle. Data are mean ± S.E. of three independent experiments, each performed in triplicate. **, significant differences (p < 0.01) between experimental groups (ANOVA followed by Newman-Keuls post test).

Having shown that geldanamycin can inhibit the interaction of Hsp90 with CB2 receptor, we next examined the possible role of Hsp90 in 2-AG-induced cell migration using geldanamycin. As shown in Fig. 5, A and B, pretreatment of HEK293 cells stably expressing FLAG-CB2 and differentiated HL-60 cells expressing endogenous CB2 with geldanamycin reduced 2-AG-induced cell migration, whereas GA alone had no significant effect on the cell migration. This inhibitory effect of geldanamycin was concentration-dependent in both types of cells. Together, these data on the inhibitory effect of geldanamycin on 2-AG-induced, CB2 receptor-mediated migration of HEK293 and differentiated HL-60 cells suggest that the interaction between Hsp90 and CB2 receptor is crucial for 2-AG-induced cell migration.

View larger version (7K): [in this window] [in a new window]   Fig. 5. Effect of geldanamycin on 2-AG-induced cell migration. A, effect of geldanamycin on 2-AG-induced migration of HEK293 cells stably expressing FLAG-CB2. Cells were pretreated with 10 µM geldanamycin for 2 h before detaching from the plate, and then they were subjected to migration assays using the Transwell cell migration system as described under Materials and Methods. Results are presented as migration index, which is the ratio of cells migrated in the presence of drug versus cells migrated in the presence of vehicle. Data shown are mean ± S.E. of three independent experiments, each performed in triplicates. B, effect of geldanamycin on 2-AG-induced migration of differentiated HL-60 cells expressing endogenous CB2. Cells were pretreated with 10 µM geldanamycin for 2 h, and then they were subjected to migration assays using the Transwell cell migration system as described under Materials and Methods. Data shown are mean ± S.E. of three independent experiments, each performed in triplicate.

View larger version (12K): [in this window] [in a new window]   Fig. 6. Effect of Hsp90 siRNA on 2-AG-induced cell migration. A, effect of Hsp90 siRNA on 2-AG-induced migration of HEK293 cells stably expressing FLAG-CB2. Cells were transfected with 2 µg of Hsp90 siRNA or a scrambled control RNA mixture for 24 h, and then they were subjected to immunoblotting (top) or migration assays (bottom) as described under Materials and Methods. Data for immunoblotting are representative for three independent experiments. Data for migration assays are mean ± S.E. of three independent experiments, each performed in triplicate. **, significant differences (p < 0.01) between experimental groups (ANOVA followed by post test). B, effect of Hsp90 siRNA on 2-AG-induced migration of differentiated HL-60 cells expressing endogenous CB2. Cells were transfected with 2 µg of Hsp90 siRNA or a scrambled control RNA mixture for 24 h, and then they were subjected to immunoblotting (top) or migration assays (bottom) as described under Materials and Methods. Data for immunoblotting are representative for three independent experiments. Migration results are presented as migration index, which is the ratio of cells migrated in the presence of drug versus cells migrated in the presence of vehicle. Data shown for migration assays are mean ± S.E. of three independent experiments, each performed in triplicate. **, significant differences (p < 0.01) between experimental groups (ANOVA followed by Newman-Keuls post test).

Effect of Geldanamycin on 2-AG-Induced Rac1-GT-Pase Activity. The small GTP-binding protein Rac1 plays a central role in the regulation of the actin-based cytoskeleton and cell movement (Ridley, 2001; Burridge and Wennerberg, 2004; Raftopoulou and Hall, 2004), and Rac1 activation is mediated by G_i protein. Because CB2 receptor is a G_i protein-coupled receptor, we investigated whether Rac1 is involved in the 2-AG-induced cell migration. As shown in Fig. 7A, in HEK293 cells stably expressing FLAG-CB2, by a pull-down assay we observed that stimulation with 2-AG provoked the rapid accumulation of GTP-bound Rac1, which reached a maximum at 5 min. Similar results were also obtained in differentiated HL-60 cells expressing endogenous CB2 receptor (Fig. 7B); i.e., treatment with 2-AG led to the increase in Rac1 activity, which reached a plateau at approximately 5 min of 2-AG stimulation. Pretreatment with SR144528 markedly inhibited the activation of Rac1 induced by 2-AG (Fig. 8), indicating that the modulation of Rac1 activity by 2-AG is mediated by CB2 receptor. However, as shown in Fig. 8, SR144528 alone had no significant effect on either GTP-bound Rac1 or total Rac1 levels.

View larger version (11K): [in this window] [in a new window]   Fig. 7. Time course of 2-AG-induced Rac1-GTPase activity. Cells were serum-starved for 18 h, and then they were stimulated with 500 nM 2-AG for the indicated times. Rac1-GTP in HEK293 cells stably expressing FLAG-CB2 (A) and differentiated HL-60 cells (B) was assessed by PAK-PBD-GST pull-down assays, respectively. Blots shown are representative of four independent experiments. In the bar graphs, results are normalized to the density of the total Rac1 band in the corresponding samples (n = 4).

View larger version (11K): [in this window] [in a new window]   Fig. 8. Effect of SR2 on 2-AG-induced Rac1-GTPase activity. Cells were serum-starved for 18 h, and then they were pretreated with 1 µM SR144528 or vehicle at 37°C incubator for 30 min, followed by stimulation with 500 nM 2-AG for 5 min. Next, the Rac1-GTP levels in HEK293 cells stably expressing FLAG-CB2 (A) and differentiated HL-60 cells (B) were measured by PAK-PBD-GST pull-down assay, respectively. Blots shown are representative of four independent experiments. In the bar graphs, results are normalized to the density of the total Rac1 band in the corresponding samples (n = 4).

View larger version (11K): [in this window] [in a new window]   Fig. 9. Effect of geldanamycin on 2-AG-induced Rac1-GTPase activity. Cells were pretreated with vehicle or 10 µM geldanamycin for 2 h, followed by stimulation with 500 nM 2-AG for 5 min, and then the Rac1-GTP levels in HEK293 cells stably expressing FLAG-CB2 (A) and differentiated HL-60 cells (B) were measured by PAK-PBD-GST pull-down assay, respectively. Blots shown are representative of four independent experiments. In the bar graphs, results are normalized to the density of the total Rac1 band in the corresponding samples (n = 4).

Effect of Dominant-Negative Form of Rac1 on 2-AG-Induced Cell Migration. After finding out that 2-AG stimulates Rac1 activity and the interaction of Hsp90 with CB2 is important for this process, the next question we asked was whether Rac1 is required for 2-AG-induced cell migration. To answer this question, the dominant-negative form of Rac1 was used. Figure 10 demonstrates that 3xHARac1T17N, the dominant-negative form of Rac1, was expressed 24 h after transfection into HEK293 cells stably expressing FLAG-CB2, as well as differentiated HL-60 cells expressing endogenous CB2. It is noteworthy that expression of the dominant-negative form of Rac1 markedly reduced 2-AG-induced cell migration in both types of cells (Fig. 10, A and B). However, expression of the dominant-negative form of Rac1 by itself had no significant effect on the cell migration. These data directly demonstrate that Rac1 plays important roles in 2-AG-induced cell migration.

View larger version (6K): [in this window] [in a new window]   Fig. 10. Effect of the dominant-negative form of Rac1 on 2-AG-induced migration. Cells were transiently transfected with the dominant-negative form of Rac1 plasmid (3xHA Rac1-T17N). At 24 h after transfection, the expression of the dominant-negative form of Rac1, and its effects on 2-AG-induced the migration of HEK293 cells stably expressing FLAG-CB2 (A) and differentiated HL-60 cells (B) were assayed. Data shown for immunoblotting are representative for three independent experiments. Migration results are presented as migration index, which is the ratio of cells migrated in the presence of drug versus cells migrated in the presence of vehicle. Data for migration assays are mean ± S.E. of three independent experiments, each performed in triplicate. **, significant differences (p < 0.01) between experimental groups (ANOVA followed by Newman-Keuls post test).

View larger version (5K): [in this window] [in a new window]   Fig. 11. Effects of PTX on 2-AG induced cell migration. HEK293 cells stably expressing FLAG-CB2 (A) or differentiated HL-60 cells expressing endogenous CB2 (B) were incubated with 100 ng/ml PTX for 18 h, and then they were subjected to migration assays using the Transwell cell migration system as described under Materials and Methods. Migration results are presented as migration index, which is the ratio of cells migrated in the presence of drug versus cells migrated in the presence of vehicle. Data shown are mean ± S.E. of three independent experiments, each performed in triplicate. **, significant differences (p < 0.01) between experimental groups (ANOVA followed by Newman-Keuls post test).

View larger version (10K): [in this window] [in a new window]   Fig. 12. Effects of PTX on 2-AG induced Rac1 GTPase activity. Cells were cultured overnight in serum-free growth medium with 100 ng/ml PTX and stimulated with 500 nM 2-AG for 5 min. The Rac1-GTP levels from HEK293 cells stably expressing FLAG-CB2 (A) and differentiated HL-60 cells expressing endogenous CB2 (B) were measured by PAK-PBD-GST pull down assays. Blots shown are representative of four independent experiments. In the bar graphs, results are normalized to the density of the total Rac1 band in the corresponding samples (n = 4).

Effect of Geldanamycin on the Interaction between G_i2 and CB2 Receptor. Because we have shown that the interaction of Hsp90 with CB2 receptor plays an important role in 2-AG-induced cell migration and Rac1 activation, the next question is how Hsp90 modulates 2-AG-induced migration response through interaction with CB2 receptor. It is well known that CB2 receptor coupled to G_i protein, and our data in Figs. 11 and 12 clearly showed that PTX-sensitive G protein of the G_i family is involved in the migratory response mediated by CB2 receptor. A recent article indicated that Hsp90 protein binds to G_i2 (Falsone et al., 2005). Based on this previous finding and our data in Figs. 11 and 12, we hypothesized that Hsp90 might act as an adaptor between CB2 receptor and G_i2, thereby regulating Rac1 activation and cell migration. To test this hypothesis, we used geldanamycin to address the role of Hsp90 in the maintenance of CB2/G_i2 coupling. In HEK293 cells stably expressing FLAG-CB2, geldanamycin pretreatment did not significantly affect the amount of G_i2 (Fig. 13A). However, treatment with geldanamycin markedly reduced the amount of G_i2 pulled down by the anti-FLAG antibody in coimmunoprecipitation and immunoblotting studies in a time-dependent manner. In addition, similar results were obtained with differentiated HL-60 cells; i.e., geldanamycin treatment significantly reduced the amount of G_i2 pulled down by the anti-CB2 antibody (Fig. 13B). These data indicate that Hsp90 might play an important role in keeping the physical coupling between CB2 receptor and its signaling component G_i2.

View larger version (26K): [in this window] [in a new window]   Fig. 13. Time course of the effect of geldanamycin on the coupling of CB2 receptor with Gi2. A, HEK293 cells stably expressing FLAG-CB2. B, differentiated HL-60 cells expressing endogenous CB2. Cells were pretreated with 10 µM GA for indicated time and stimulated with 500 nM 2-AG for 5 min. Membranes were prepared and subjected to coimmunoprecipitation with the anti-CB2 antibody. The samples were immunoblotted with the anti-Gi2 and the anti-CB2 antibodies. The experiment was repeated twice, with similar results.

	Discussion

Top Abstract Materials and Methods Results Discussion References

Many cellular events depend on the regulated protein-protein interactions. Discovering novel protein interactions should facilitate the understanding of the molecular mechanisms underlying biological processes. In the current study, we first identified Hsp90 as a possible constitutive interacting protein of CB2 receptor by immunoprecipitation and mass spectrometry. The interaction between Hsp90 and CB2 receptor in FLAG-CB2-transfected HEK293 cells was found to be specific, because Hsp90 was not immunoprecipitated with either anti-FLAG or anti-CB2 antibodies in HEK293 cells transfected with an empty vector. The interaction was also seen in differentiated HL-60 cells, which express endogenous CB2 receptors. The rationales for us to choose HL-60 cells were as follows: 1) HL-60 is a human promyelocytic leukemia cell line, from which CB2 receptor was originally cloned (Munro et al., 1993); and 2) differentiated HL-60 cells are established models widely used for studying the mechanisms of leukocyte migration (Hauert et al., 2002; Xu et al., 2003).

View larger version (24K): [in this window] [in a new window]   Fig. 14. Working model concerning the involvement of Hsp90 in CB2 receptor-mediated cell migration. Hsp90 may function as a scaffold orienting Gi2 to interact with the CB2 receptor or stabilizing CB2 receptor on the cell surface, thus facilitating CB2-mediated signaling to cell migration through the Gi-Rac1 pathway.

In this study, we have confirmed that 2-AG can induce migration of HEK293 cells stably expressing CB2 receptor, as well as HL-60 cells differentiated into neutrophil-like cells. Furthermore, we have demonstrated that CB2 antagonist SR144528 can block 2-AG-induced migration of both types of cells. More importantly, we have shown that pretreatment with geldanamycin markedly reduced the 2-AG-induced, CB2 receptor-mediated migration of HEK293 as well as differentiated HL-60 cells. Furthermore, in Hsp90 knock-down experiments performed with Hsp90 siRNA, we have shown that decreasing the cellular expression of Hsp90 reduced 2-AG-induced migration. These data clearly demonstrate that the interaction between Hsp90 and CB2 is essential for 2-AG-induced, CB2 receptor-mediated cell migration.

How can Hsp90 play a role in the 2-AG-induced, CB2 receptor-mediated cell migration? Before answering this question, we must first understand the signaling pathways of 2-AG-induced cell migration. Rho-families of small GTPases are well known, key regulators in cell migration (Ridley, 2001; Burridge and Wennerberg, 2004; Raftopoulou and Hall, 2004). Previous reports have found that the activation of different component of Rho-families depends upon different signaling pathways; i.e., the activation of RhoA involves the G_12/13-mediated pathway, whereas the activation of Rac depends on the G_i-mediated pathway (Xu et al., 2003). It is well known that CB2 receptor is a G_i protein-coupled receptor. As a first step in elucidating the molecular mechanism by which 2-AG induces cell migration, we studied the effects of 2-AG on Rac1 activity. Our data demonstrate that 2-AG induced a time-dependent enhancement of Rac1 activity, and this enhancement was inhibited by CB2 antagonist SR144528, suggesting that Rac1-GTPases may be involved in 2-AG-induced cell migration. Our hypothesis that Rac1-GTPases may be involved in 2-AG-induced cell migration is further supported by our data demonstrating that the dominant-negative form of Rac1 markedly inhibited 2-AG-induced cell migration. To our knowledge, this study is the first to directly establish the involvement of Rac1 in cannabinoid-induced cell migration using the dominant-negative form of the Rho-families of small GTPases. These data are consistent with a recent report on the effect of the dominant-negative form of Rac1 on N-formyl-L-methionyl-L-leucyl-L-phenylalanine-induced cell migration (Pestonjamasp et al., 2006). In the current study, we have found that pretreatment with PTX inhibited the cell migration induced by 2-AG in both types of cells. These data confirm that G_i participates in the migratory response mediated by CB2 receptor. Furthermore, pretreatment of both two types of cells with PTX attenuated the 2-AG-induced Rac1 GTPase activity, again confirming the involvement of G_i protein. Taken together, our experimental data support the hypothesis that 2-AG-induced, CB2 receptor-mediated cell migration involves Rac1 activation through PTX-sensitive G proteins of the G_i class.

In this study, we have found that pretreatment of cells with geldanamycin inhibited 2-AG-induced activation of Rac1. In addition, we have shown that pretreatment of cells with geldanamycin decreased 2-AG-induced cell migration. A previous study has reported the effects of geldanamycin on proteinase-activated receptor-1-stimulated, thrombin receptor-mediated changes in cell morphology and cytoskeleton (Pai et al., 2001). To our knowledge, the current study is the first to demonstrate a modulatory effect of geldanamycin on ligand-induced, GPCR-mediated cell migration. These data on the modulatory effects of geldanamycin on 2-AG-induced Rac1 activity, and 2-AG-induced cell migration, support the hypothesis that Hsp90 regulates 2-AG-induced cell migration by modulating 2-AG-induced Rac1 activity.

How might Hsp90 modulate 2-AG-induced Rac1 activity? The current study indicated that Hsp90 acts upstream of Rac1, because geldanamycin blocked 2-AG-induced activation of Rac1. In a previous publication on Hsp90 interactome analysis, it has been shown that Hsp90 can interact with G_i2 (Falsone et al., 2005). Using PTX, in this study we also confirmed the involvement of G_i protein in 2-AG-induced, CB2 receptor-mediated Rac1 activation and cell migration. Therefore, we hypothesized that Hsp90 may regulate CB2-mediated Rac1 activation through modulation of the coupling between CB2 receptor and G_i2. This hypothesis is supported directly by our experimental data demonstrating that treatment with geldanamycin decreased the physical coupling of CB2 receptor with G_i2. Therefore, it is likely that Hsp90 serves as a scaffold to keep the CB2 receptor and its signaling components, including G_i2, in proximity, thus ensuring proper signaling transduction. To our knowledge, this is the first time that Hsp90 has been shown to play a critical role in the coupling of a GPCR to its G protein. However, it is also possible that Hsp90 may be necessary to stabilize the receptor on the cell surface.

Compared with other heat shock proteins, Hsp90 is distinguished by its specific interactions with various signaling proteins and its important role in signal transduction under nonstress conditions. Our studies add support to this premise by demonstrating that geldanamycin not only inhibited the interaction between CB2 receptor and Hsp90 but also prevented the CB2/G_i2 coupling, the activation of Rac1, and the subsequent cell migration induced by 2-AG.

In conclusion, as outlined in Fig. 14, this study demonstrates that Hsp90 is essential for CB2-mediated cell migration, and it reveals a novel role of Hsp90 in the signaling events mediated by a G protein-coupled receptor.

	Footnotes

 
This work is supported in part by National Institutes of Health grants DA11551 and EY13632.

Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.

doi:10.1124/mol.107.036566.

ABBREVIATIONS: GPCR, G protein-coupled receptor; CB, cannabinoid; 2-AG, 2-arachidonoylglycerol; Hsp90, 90-kDa heat shock protein; HEK, human embryonic kidney; SR144528, SR2, N-[(1S)-endo-1,3,3-trimethyl-bicyclo-[2.2.1]-heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide; siRNA, short interfering RNA; DMEM, Dulbecco's modified Eagle's medium; DMSO, dimethyl sulfoxide; MALDI-TOF, matrix-assisted laser desorption ionization/time of flight; MS, mass spectrometry; PAGE, polyacrylamide gel electrophoresis; ACN, acetonitrile; TBS-T, Tris-buffered saline/Tween 20; ANOVA, analysis of variance; PTX, pertussis toxin; GA, geldanamycin; PAK-PBD-GST, p21-activated kinase-PAK binding domain-glutathionetransferase.

Address correspondence to: Dr. Zhao-Hui Song, Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40292. E-mail: zhsong{at}louisville.edu

	References

Top Abstract Materials and Methods Results Discussion References

 
Alberich Jordà M, Rayman N, Tas M, Verbakel SE, Battista N, van Lom K, Lowenberg B, Maccarrone M, and Delwel R (2004) The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner. Blood 104: 526–534.[Abstract/Free Full Text]

Bockaert J, Roussignol G, Becamel C, Gavarini S, Joubert L, Dumuis A, Fagni L, and Marin P (2004) GPCR-interacting proteins (GIPs): nature and functions. Biochem Soc Trans 32: 851–855.[CrossRef][Medline]

Bohen SP, Kralli A, and Yamamoto KR (1995) Hold'em and fold'em: chaperones and signal transduction. Science 268: 1303–1304.[Free Full Text]

Brady AE and Limbird LE (2002) G protein-coupled receptor interacting proteins: emerging roles in localization and signal transduction. Cell Signal 14: 297–309.[CrossRef][Medline]

Buckley NE, Burbridge D, Buranapramest M, Ferguson T, and Paau RY (2006) Experimental methods to study the role of the peripheral cannabinoid receptor in immune function. Methods Mol Med 123: 19–40.[Medline]

Buckley NE, Hansson S, Harta G, and Mezey E (1998) Expression of the CB1 and CB2 receptor messenger RNAs during embryonic development in the rat. Neuroscience 82: 1131–1149.[CrossRef][Medline]

Burridge K and Wennerberg K (2004) Rho and Rac take center stage. Cell 116: 167–179.[CrossRef][Medline]

Falsone SF, Gesslbauer B, Tirk F, Piccinini AM, and Kungl AJ (2005) A proteomic snapshot of the human heat shock protein 90 interactome. FEBS Lett 579: 6350–6354.[CrossRef][Medline]

Feng W, Cai J, Pierce WM Jr, and Song ZH (2002) Expression of CB2 cannabinoid receptor in Pichia pastoris. Protein Expr Purif 26: 496–505.[CrossRef][Medline]

Gaestel M (2006) Molecular chaperones in signal transduction. Handb Exp Pharmacol 172: 93–109.[Medline]

Gao ZG and Jacobson KA (2006) Keynote review: allosterism in membrane receptors. Drug Discov Today 11: 191–202.[CrossRef][Medline]

Hauert AB, Martinelli S, Marone C, and Niggli V (2002) Differentiated HL-60 cells are a valid model system for the analysis of human neutrophil migration and chemotaxis. Int J Biochem Cell Biol 34: 838–854.[CrossRef][Medline]

Jordà MA, Rayman N, Valk P, De Wee E, and Delwel R (2003) Identification, characterization, and function of a novel oncogene: the peripheral cannabinoid receptor Cb2. Ann N Y Acad Sci 996: 10–16.[CrossRef][Medline]

Jordà MA, Verbakel SE, Valk PJ, Vankan-Berkhoudt YV, Maccarrone M, Finazzi-Agro A, Lowenberg B, and Delwel R (2002) Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. Blood 99: 2786–2793.[Abstract/Free Full Text]

Kishimoto S, Gokoh M, Oka S, Muramatsu M, Kajiwara T, Waku K, and Sugiura T (2003) 2-Arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism. J Biol Chem 278: 24469–24475.[Abstract/Free Full Text]

Kogan NM and Mechoulam R (2006) The chemistry of endocannabinoids. J Endocrinol Invest 29: 3–14.[Medline]

Lunn CA, Reich EP, and Bober L (2006) Targeting the CB2 receptor for immune modulation. Expert Opin Ther Targets 10: 653–663.[CrossRef][Medline]

Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561–564.[CrossRef][Medline]

Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83–90.[CrossRef][Medline]

Munro S, Thomas KL, and Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61–65.[CrossRef][Medline]

Oka S, Ikeda S, Kishimoto S, Gokoh M, Yanagimoto S, Waku K, and Sugiura T (2004) 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL-1 human eosinophilic leukemia cells and human peripheral blood eosinophils. J Leukoc Biol 76: 1002–1009.[Abstract/Free Full Text]

Pai KS, Mahajan VB, Lau A, and Cunningham DD (2001) Thrombin receptor signaling to cytoskeleton requires Hsp90. J Biol Chem 276: 32642–32647.[Abstract/Free Full Text]

Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74: 129–180.[CrossRef][Medline]

Pertwee RG (2005) Pharmacological actions of cannabinoids. Handb Exp Pharmacol 168: 1–51.[CrossRef][Medline]

Pestonjamasp KN, Forster C, Sun C, Gardiner EM, Bohl B, Weiner O, Bokoch GM, and Glogauer M (2006) Rac1 links leading edge and uropod events through Rho and myosin activation during chemotaxis. Blood 108: 2814–2820.[Abstract/Free Full Text]

Pratt WB (1997) The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase. Annu Rev Pharmacol Toxicol 37: 297–326.[CrossRef][Medline]

Raftopoulou M and Hall A (2004) Cell migration: Rho GTPases lead the way. Dev Biol 265: 23–32.[CrossRef][Medline]

Ridley AJ (2001) Rho family proteins: coordinating cell responses. Trends Cell Biol 11: 471–477.[CrossRef][Medline]

Rutherford SL and Zuker CS (1994) Protein folding and the regulation of signaling pathways. Cell 79: 1129–1132.[CrossRef][Medline]

Song ZH and Bonner TI (1996) A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol Pharmacol 49: 891–896.[Abstract]

Song ZH, Slowey CA, Hurst DP, and Reggio PH (1999) The difference between the CB(1) and CB(2) cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212-2 for CB(2). Mol Pharmacol 56: 834–840.[Abstract/Free Full Text]

Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, and Pavletich NP (1997) Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89: 239–250.[CrossRef][Medline]

Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, and Waku K (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215: 89–97.[CrossRef][Medline]

Sugiura T, Oka S, Gokoh M, Kishimoto S, and Waku K (2004) New perspectives in the studies on endocannabinoid and cannabis: 2-arachidonoylglycerol as a possible novel mediator of inflammation. J Pharmacol Sci 96: 367–375.[CrossRef][Medline]

Sugiura T and Waku K (2000) 2-Arachidonoylglycerol and the cannabinoid receptors. Chem Phys Lipids 108: 89–106.[CrossRef][Medline]

Tilakaratne N and Sexton PM (2005) G-Protein-coupled receptor-protein interactions: basis for new concepts on receptor structure and function. Clin Exp Pharmacol Physiol 32: 979–987.[CrossRef][Medline]

Ui M and Katada T (1990) Bacterial toxins as probe for receptor-Gi coupling. Adv Second Messenger Phosphoprotein Res 24: 63–69.[Medline]

Xu J, Wang F, Van Keymeulen A, Herzmark P, Straight A, Kelly K, Takuwa Y, Sugimoto N, Mitchison T, and Bourne HR (2003) Divergent signals and cytoskeletal assemblies regulate self-organizing polarity in neutrophils. Cell 114: 201–214.[CrossRef][Medline]

Zhang R, Kim TK, Qiao ZH, Cai J, Pierce WM Jr, and Song ZH (2007) Biochemical and mass spectrometric characterization of the human CB2 cannabinoid receptor expressed in Pichia pastoris–importance of correct processing of the N-terminus. Protein Expr Purif, in press.

This Article Abstract Full Text (PDF) All Versions of this Article: mol.107.036566v1 72/5/1289    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by He, F. Articles by Song, Z.-H. Search for Related Content PubMed PubMed Citation Articles by He, F. Articles by Song, Z.-H.